Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.10%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    86,063.72
    -1,823.29 (-2.07%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Today's Research Reports on Stocks to Watch: Axovant Sciences and Gevo

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Gevo and Axovant Sciences had something in common on Tuesday. Both stocks saw significant moves north despite any news nor catalyst.

RDI Initiates Coverage on:

Axovant Sciences Ltd.
https://rdinvesting.com/news/?ticker=AXON

Gevo, Inc.
https://rdinvesting.com/news/?ticker=GEVO

Axovant Sciences Ltd. was up 14.43% at the close on Tuesday on about 1.5 million shares traded. There was no catalyst nor news from the company to explain the rally. It was about two weeks ago that Axovant reported first quarter financial results. The company reported a loss of $51.9 million in its fiscal first quarter. On a per-share basis, the loss was 48 cents. During a corporate update, Pavan Cheruvu, MD, Chief Executive Officer of Axovant announced "Axovant is methodically rebuilding its clinical pipeline with the goal of becoming a leader in neurological gene therapies. We are focused on transformative approaches that can have a significant impact on the lives of patients suffering from debilitating or potentially life-threatening conditions. With the promotion of Ilise Lombardo, MD, to Chief Medical Officer, and the addition of several key members to our leadership team, we are well-positioned to initiate two potentially pivotal clinical studies with AXO-Lenti-PD and AXO-AAV-OPMD". He further added, "We also continue to identify opportunities to further strengthen our pipeline, focusing on programs that will be in the clinic in the next 12 to 18 months and that have genetically-identifiable targets in indications with well-characterized biology. I look forward to providing additional updates as these efforts progress."

ADVERTISEMENT

Access RDI's Axovant Sciences Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=AXON

Gevo, Inc. shares closed up nearly 19% on Tuesday with a little over 4 million shares traded. There was no news from the company to explain the jump but the stock has been seeing momentum for the past week. It was earlier in the month that the renewable chemicals and biofuels company announced second quarter results. CEO Patrick R. Gruber had said during the earnings call, "What a difference 6 months can make. If you compare our balance sheet from the end of the year till now, you'll see that we've made quite the improvements. Cash on hand in December was $11.6 million whereas at July 31, last week, we held more than $40 million in cash in the balance sheet. Our total liabilities last December were more than $25 million, now they're less than $17 million. The additional cash that we now have will make it easier for us to move forward with plans to make the company profitable. This change is significant and shouldn't be underestimated. It makes discussions with vendors, customers, strategic partners, much more productive as it removes any doubt that we expect to be around for the long run." CAO Bradford K. Towne stated on the call, "Gevo reported revenue in the second quarter of 2018 of $9.4 million as compared to $7.5 million in the same period in 2017. The increase in revenue during the second quarter of 2018 is primarily a result of the production and sale of approximately $8.8 million of ethanol, isobutanol and distiller grains at the Luverne plant as compared to $6.8 million in the second quarter of 2017. This increase in revenue was mainly due to increased ethanol production and higher distiller grain prices in the second quarter of 2018 versus the same period in 2017."

Access RDI's Gevo, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GEVO

Our Actionable Research on Axovant Sciences Ltd. (NASDAQ: AXON) and Gevo, Inc. (NASDAQ: GEVO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com